keyword
MENU ▼
Read by QxMD icon Read
search

Esophagogastric cancer

keyword
https://www.readbyqxmd.com/read/28722083/-a-perception-of-the-development-trend-of-radiological-t-staging-in-gastric-cancer-through-uicc-ajcc-8-th-edition
#1
Lei Tang
More and more emphases were put on pre-therapy staging following the promotion of multidisciplinary team(MDT) collaboration and individualized medicine in gastric cancer. However, the accuracy of traditional radiology staging system which applies mechanically pathological staging is not satisfactory during clinical practice, therefore, the objectivity of treatment decisions is affected. Under such conditions, the newly introduced staging system from Union for International Cancer Control/American Joint Committee on Cancer(UICC/AJCC)(8(th) edition) divided out an independent cTNM system for the first time, and summarized the application range, operation specification and staging criteria...
July 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28721567/modified-double-layer-anastomosis-for-minimally-invasive-esophagectomy-an-effective-way-to-prevent-leakage-and-stricture
#2
Yong Yuan, Xiao-Xi Zeng, Yong-Fan Zhao, Long-Qi Chen
BACKGROUND: Anastomotic leakage and stricture contribute to a large number of mortality and morbidity after esophagectomy. The aim of this work is to evaluate the outcome of modified double-layer hand-sewn esophagogastric anastomosis during minimally invasive esophagectomy for esophageal cancer. METHODS: The clinicopathological data of 176 consecutive esophageal cancer patients who underwent cervical esophagogastric anastomosis using modified double-layer hand-sewn technique after radical esophagectomy were retrospectively reviewed...
July 18, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28637800/pharmacokinetics-biodistribution-and-radiation-dosimetry-for-89-zr-trastuzumab-in-patients-with-esophagogastric-cancer
#3
Joseph A O'Donoghue, Jason S Lewis, Neeta Pandit-Taskar, Stephen E Fleming, Heiko Schoder, Steven M Larson, Volkan Beylergil, Shutian Ruan, Serge Lyashchenko, Pat B Zanzonico, Wolfgang Andreas Weber, Jorge A Carrasquillo, Yelena Y Janjigian
Trastuzumab with chemotherapy improves clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA). Despite the therapeutic benefit, responses are rarely complete and the majority of patients develop progression. This is the first report evaluating (89)Zr-trastuzumab in HER2-positive EGA in which we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry. Methods: Trastuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr...
June 21, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28616596/laparoscopic-endoscopic-cooperative-surgery-lecs-for-the-upper-gastrointestinal-tract
#4
REVIEW
Tatsuo Matsuda, Souya Nunobe, Manabu Ohashi, Naoki Hiki
We developed the laparoscopic and endoscopic cooperative surgery (LECS) technique, which combines endoscopic submucosal dissection (ESD) and laparoscopic gastric resection to resect gastric submucosal tumors (SMTs). Many researchers have reported LECS to be a feasible technique for gastric submucosal tumor resection regardless of tumor location, including the esophagogastric junction (EGJ). Recently, the Japanese National Health Insurance system approved LECS for insurance coverage, and it is now widely applied for gastric submucosal tumor resection...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28589183/the-clinicopathologic-characteristics-and-prognostic-factors-of-gastroesophageal-junction-tumors-according-to-siewert-classification
#5
Bala Başak Öven Ustaalioğlu, Metin Tilki, Ali Sürmelioğlu, Ahmet Bilici, Can Gönen, Recep Ustaalioğlu, Özlem Balvan, Mehmet Aliustaoğlu
OBJECTIVE: The treatment of gastroesophageal junction tumors remains controversial due to confusion on whether they should be considered as primary esophageal or as gastric tumors. The incidence of these tumors with poor prognosis has increased, thus creating scientific interest on gastroesophageal cancers. Esophagogastric cancers are classified according to their location by Siewert, and the treatment of each type varies. We evaluated the prognostic factors and differences in clinicopathologic factors of patients with gastroesophageal junction tumor, who have been treated and followed-up in our clinics...
2017: Turk J Surg
https://www.readbyqxmd.com/read/28561677/immunotherapy-for-esophageal-and-gastric-cancer
#6
Ronan J Kelly
PD-L1 upregulation occurs in approximately 40% of gastroesophageal cancers. However, unlike other solid tumors, there is minimal PD-L1 expressed on the cancer cells; rather, expression occurs predominantly on infiltrating myeloid cells. Preliminary clinical data involving single-agent PD-1/PD-L1 inhibitors in metastatic gastroesophageal cancer have reported response rates of 22%-27% for patients with PD-L1(+) tumors and 10%-17% for unselected patients. The phase III ONO-4538-12 (ATTRACTION 2) trial has demonstrated an improved overall survival for nivolumab compared with placebo for patients with heavily pretreated gastric cancer...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28556024/cancer-of-the-esophagus-and-esophagogastric-junction-major-changes-in-the-american-joint-committee-on-cancer-eighth-edition-cancer-staging-manual
#7
Thomas W Rice, Donna M Gress, Deepa T Patil, Wayne L Hofstetter, David P Kelsen, Eugene H Blackstone
Answer questions and earn CME/CNE New to the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual for epithelial cancers of the esophagus and esophagogastric junction are separate, temporally related cancer classifications: 1) before treatment decision (clinical); 2) after esophagectomy alone (pathologic); and 3) after preresection therapy followed by esophagectomy (postneoadjuvant pathologic). The addition of clinical and postneoadjuvant pathologic stage groupings was driven by a lack of correspondence of survival, and thus prognosis, between both clinical and postneoadjuvant pathologic cancer categories (facts about the cancer) and pathologic categories...
July 8, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28551654/overexpression-of-egfr-as-an-independent-prognostic-factor-in-adenocarcinoma-of-the-esophagogastric-junction
#8
Kenichi Aratani, Shuhei Komatsu, Daisuke Ichikawa, Takuma Ohashi, Mahito Miyamae, Wataru Okajima, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Toshiyuki Kosuga, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Hitoshi Tsuda, Eigo Otsuji
BACKGROUND: Adenocarcinoma of the esophagogastric junction (AEG) has increased in Western and Eastern countries, and its prognosis remains poor. We tested whether epidermal growth factor receptor (EGFR), that is overexpressed in various tumors, acts as a cancer-promoting gene through overexpression in AEG. MATERIALS AND METHODS: We analyzed 104 primary AEG tumors which were curatively resected in our hospital between 2000 and 2010. RESULTS: Overexpression of EGFR protein was detected in 47% primary AEG tumor samples, and significantly associated with venous and lymphatic invasion, tumor depth and lymph node metastasis...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28529581/expression-of-serum-and-glucocorticoid-regulated-kinase-1-and-its-association-with-clinicopathological-factors-and-the-survival-of-patients-with-adenocarcinoma-of-the-esophagogastric-junction
#9
Shegan Gao, Dan Wang, Guoqiang Kong, Shuoguo Li, Wei Wang, Huizhi Wang, Fuyou Zhou
While the aberrant expression and the controversial results of serum- and glucocorticoid-regulated kinase (SGK1) have been reported in a number of malignancies, the expression of SGK1 and its possible association with the progression of adenocarcinoma in the esophagogastric junction (AEG) remain to be elucidated. To the best of our knowledge, the expression and localization of SGK1 was examined for the first time in the present study in cancerous and adjacent tissue from 60 patients with AEG, and compared with 20 healthy mucosa control tissue samples...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28514311/trends-in-esophageal-and-esophagogastric-junction-cancer-research-from-2007-to-2016-a-bibliometric-analysis
#10
REVIEW
Yan Miao, Ran Liu, Yuepu Pu, Lihong Yin
BACKGROUND: This study aimed to analyze the scientific outputs of esophageal and esophagogastric junction (EGJ) cancer and construct a model to quantitatively and qualitatively evaluate pertinent publications from the past decade. METHODS: Publications from 2007 to 2016 were retrieved from the Web of Science Core Collection database. Microsoft Excel 2016 (Redmond, WA) and the CiteSpace (Drexel University, Philadelphia, PA) software were used to analyze publication outcomes, journals, countries, institutions, authors, research areas, and research frontiers...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28501094/the-management-of-esophagogastric-cancers-enters-a-new-era
#11
EDITORIAL
Manish A Shah
No abstract text is available yet for this article.
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501091/update-on-gastroesophageal-adenocarcinoma-targeted-therapies
#12
REVIEW
Steven B Maron, Daniel V T Catenacci
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) incidence is rising. GC and EGJ, together, are treated uniformly in the metastatic setting as GEC. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to date-only first-line anti-HER2 therapy for ERBB2 amplification and second-line anti-VEGFR2 therapy...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501090/antiangiogenic-therapy-in-gastroesophageal-cancer
#13
REVIEW
Zhaohui Jin, Harry H Yoon
Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501037/portuguese-version-of-the-eortc-qlq-oes18-and-qlq-og25-for-health-related-quality-of-life-assessment
#14
Miguel Relvas-Silva, Rui Almeida Silva, Mário Dinis-Ribeiro
INTRODUCTION: Health-related quality of life assessment is increasingly important as it can help both clinical research and care for patients, particularly among oncological patients. Quality of Life Questionnaire - OES18 (esophageal module) and Quality of Life Questionnaire - OG25 (esophagogastric module) are the European Organization for Research and Treatment of Cancer modules for the evaluation of quality of life in patients with esophageal and esophagogastric cancers, respectively...
January 31, 2017: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28497176/five-weekly-s-1-plus-cisplatin-therapy-combined-with-trastuzumab-therapy-in-her2-positive-gastric-cancer-a-phase-ii-trial-and-biomarker-study-wjog7212g
#15
Yuji Miura, Yasutaka Sukawa, Shuichi Hironaka, Misuzu Mori, Kazuhiro Nishikawa, Shinya Tokunaga, Hiroyuki Okuda, Takeshi Sakamoto, Keisei Taku, Kazuo Nishikawa, Toshikazu Moriwaki, Yuji Negoro, Yutaka Kimura, Keita Uchino, Katsunori Shinozaki, Hiroharu Shinozaki, Nobuyuki Musha, Hirotsugu Yoshiyama, Takashi Tsuda, Yoshinori Miyata, Naotoshi Sugimoto, Tsuyoshi Shirakawa, Miki Ito, Kimio Yonesaka, Kenichi Yoshimura, Narikazu Boku, Katsuhiko Nosho, Toshimi Takano, Ichinosuke Hyodo
BACKGROUND: Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear. METHODS: Patients received 5-weekly SP therapy (S-1 at 40-60 mg twice daily for 21 days plus cisplatin at 60 mg/m(2) on day 8, every 5 weeks) plus trastuzumab therapy (first dose of 8 mg/kg, then 6 mg/kg every 3 weeks)...
May 11, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28487496/programmed-death-1-polymorphisms-is-associated-with-risk-of-esophagogastric-junction-adenocarcinoma-in-the-chinese-han-population-a-case-control-study-involving-2-740-subjects
#16
Weifeng Tang, Shuchen Chen, Yu Chen, Jihong Lin, Jiangbo Lin, Yafeng Wang, Chao Liu, Mingqiang Kang
Single nucleotide polymorphisms (SNPs) in Programmed cell death 1 (PD-1) gene may contribute to the development of cancer. In this study, we selected PD-1 rs10204525 T>C, rs2227982 A>G, rs36084323 T>C and rs7421861 A>G polymorphisms and designed a hospital-based case-control study to determine the potential relationship between these functional SNPs in PD-1 gene and esophagogastric junction adenocarcinoma (EGJA) risk. A total of 1,063 EGJA patients and 1,677 controls were enrolled from Eastern Chinese Han population...
June 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28449521/cancer-of-the-esophagus-and-esophagogastric-junction-an-8-th-edition-staging-primer
#17
EDITORIAL
Claire L Donohoe, Alexander W Phillips
No abstract text is available yet for this article.
March 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28447000/8th-edition-ajcc-uicc-staging-of-cancers-of-the-esophagus-and-esophagogastric-junction-application-to-clinical-practice
#18
Thomas W Rice, Deepa T Patil, Eugene H Blackstone
The 8th edition of the American Joint Committee on Cancer (AJCC) staging of epithelial cancers of the esophagus and esophagogastric junction (EGJ) presents separate classifications for clinical (cTNM), pathologic (pTNM), and postneoadjuvant (ypTNM) stage groups. Histopathologic cell type markedly affects survival of clinically and pathologically staged patients, requiring separate groupings for each cell type, but ypTNM groupings are identical for both cell types. Clinical categories, typically obtained by imaging with minimal histologic information, are limited by resolution of each method...
March 2017: Annals of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/28429196/expression-of-programmed-cell-death-protein-1-by-tumor-infiltrating-lymphocytes-and-tumor-cells-is-associated-with-advanced-tumor-stage-in-patients-with-esophageal-adenocarcinoma
#19
Dagmar Kollmann, Desislava Ignatova, Julia Jedamzik, Yun-Tsan Chang, Gerd Jomrich, Matthias Paireder, Ivan Kristo, Dmitry Kazakov, Michal Michal, Antonio Cozzio, Wolfram Hoetzenecker, Tobias Schatton, Reza Asari, Matthias Preusser, Emmanuella Guenova, Sebastian F Schoppmann
BACKGROUND: Despite recent advances in the therapy for adenocarcinoma of the esophagogastric junction (AEG), overall prognosis remains poor. Programmed cell death protein 1 (PD1) is a co-inhibitory receptor primarily expressed by T-cells. Tumor cells can escape anticancer immune responses by triggering the PD1 pathway. Moreover, PD1 receptor engagement on cancer cells may trigger tumor-intrinsic growth signals. This study aimed to evaluate the potential clinical relevance of PD1 expression by tumor-infiltrating lymphocytes (TILs) and cancer cells in the AEG...
April 20, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28425657/different-time-trend-and-management-of-esophagogastric-junction-adenocarcinoma-in-three-asian-countries
#20
Waku Hatta, Daniel Tong, Yeong Yeh Lee, Shin Ichihara, Noriya Uedo, Takuji Gotoda
Esophagogastric junction (EGJ) adenocarcinoma has been on the increase in Western countries. However, in Asian countries, data on the incidence of EGJ adenocarcinoma are evidently lacking. In the present review, we focus on the current clinical situation of EGJ adenocarcinoma in three Asian countries: Japan, Hong Kong, and Malaysia. The incidence of EGJ adenocarcinoma has been reported to be gradually increasing in Malaysia and Japan, whereas it has stabilized in Hong Kong. However, the number of cases in these countries is comparatively low compared with Western countries...
April 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
keyword
keyword
119338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"